CMS Proposes Tweaking Drug Negotiation Policy To Prevent Combo Drug Gaming

Why It Matters

If adopted, the rule could force pharmaceutical firms to negotiate prices on a larger share of combo therapies, curbing cost growth for Medicare and reducing taxpayer burden. It also signals heightened regulatory scrutiny of pricing maneuvers that inflate drug costs.

Key Takeaways

• CMS aims to close loophole allowing new combo formulations to dodge negotiation
• Proposal expands definition of “combination drug” under the Inflation Reduction Act
• Manufacturers may need to renegotiate pricing for dozens of existing combo products
• Expected to save Medicare billions by preventing price‑inflation gaming

Pulse Analysis

The Medicare drug‑price negotiation provision, enacted under the 2022 Inflation Reduction Act, was designed to lower out‑of‑pocket costs for seniors by forcing manufacturers to submit price offers for high‑spending drugs. However, the rule originally exempted many combination products, creating an incentive for companies to bundle a new molecule, dosage form, or delivery method with an existing, negotiable drug. This tactic—often called "combo drug gaming"—has allowed manufacturers to keep prices high while technically complying with the law.

CMS’s latest proposal seeks to redefine what qualifies as a combination drug, capturing products that add a modest new ingredient, alter the formulation, or change the route of administration. The agency will issue guidance on thresholds for “substantial” changes, effectively pulling a swath of combo therapies—ranging from oncology regimens to chronic‑disease inhalers—into the negotiation framework. Pharmaceutical firms are expected to reassess their product pipelines, as the expanded scope could trigger mandatory price discussions for dozens of drugs that were previously exempt.

The broader impact extends beyond immediate cost savings. By limiting a key loophole, CMS aims to reinforce the credibility of the Medicare negotiation program and encourage more transparent pricing across the industry. Health‑plan administrators and patient advocacy groups anticipate reduced premium pressures, while insurers may see lower drug spend volatility. For policymakers, the move underscores a growing willingness to tighten regulatory oversight in pursuit of sustainable drug‑cost containment for the nation’s aging population.